Company performance
Add to research
Current Price
as of Apr 25, 2025$41.33
P/E Ratio
283.47
Market Cap
$6.56B
Description
Add to research
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
Metrics
Add to research
Overview
- HQMorrisville, NC
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerTGTX
- Price$41.33+2.56%
Trading Information
- Market cap$6.56B
- Float90.04%
- Average Daily Volume (1m)2,851,798
- Average Daily Volume (3m)2,698,669
- EPS$0.16
Company
- Revenue$329.00M
- Rev growth (1yr)40.80%
- Net income$23.38M
- Gross margin88.22%
- EBITDA margin12.83%
- EBITDA$42.21M
- EV$4.77B
- EV/Revenue14.49
- P/E283.47
- P/S20.14
- P/B28.96
- Debt/Equity114.10
Documents
Add to research
SEC Filings
Earnings Calls